Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Total Liabilities readings, the most recent being $202.9 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 14.32% to $202.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $202.9 million, a 14.32% decrease, with the full-year FY2025 number at $216.0 million, down 12.84% from a year prior.
  • Total Liabilities hit $202.9 million in Q4 2025 for Enanta Pharmaceuticals, down from $216.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $257.3 million in Q2 2023 to a low of $31.7 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $209.5 million (2025), compared with a mean of $150.2 million.
  • Biggest five-year swings in Total Liabilities: dropped 16.92% in 2022 and later surged 445.34% in 2023.
  • Enanta Pharmaceuticals' Total Liabilities stood at $56.2 million in 2021, then decreased by 16.92% to $46.7 million in 2022, then skyrocketed by 406.7% to $236.6 million in 2023, then grew by 0.09% to $236.8 million in 2024, then decreased by 14.32% to $202.9 million in 2025.
  • The last three reported values for Total Liabilities were $202.9 million (Q4 2025), $216.0 million (Q3 2025), and $221.8 million (Q2 2025) per Business Quant data.